Pfizer Inc Patent Portfolio Statistics

tip_user1

Pfizer Inc.

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Pfizer Inc. look like?

Assignee Art Units
Total Applications: 3,142 1,752,003
Granted Patents: 1,218 910,450
Grant Index 66.96% ↑ 66.03%
Abandoned/Rejected Applications: 601 (33.04%) 468,451 (33.97%)
In-Process Applications: 1,321 373,102
Average Grant Time: 3.0 Years ↑ 2.78 Years
Average Office Actions: 1.87 ↑ 1.69

Which Technology Area Pfizer Inc. is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 218
1625 Organic Chemistry 188
1626 Organic Chemistry 140
1614 – 90
1648 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 90

How many patents are Pfizer Inc. filing every year?

Year Total Applications Predicted
2022 0* 57
2021 7* 44
2020 25 48
2019 34 34
2018 27 –
2017 31 –
2016 41 –
2015 32 –
2014 34 –
2013 41 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Pfizer Inc. in USPTO?

Publication number: US20220089580A1
Application number: 17/544,303

Abstract:
This invention relates to compounds of Formula (I)

or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

Publication date: 2022-03-24
Applicant: Pfizer Inc.
Inventors: Cho-Schultz Sujin

Publication number: US20220089613A1
Application number: 17/539,948

Abstract:
The present invention relates to compounds and pharmaceutically acceptable salts of Formulas A and B:wherein A, B, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer’s disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ.

Publication date: 2022-03-24
Applicant: Pfizer Inc.
Inventors: Nukui Seiji

Publication number: US20220207454A1
Application number: 17/607,341

Abstract:
Lean manufacturing principles are integrated into computing components for the generation, collection, analysis, and propagation of real-time manufacturing and supply operations data. A set of role card objects determined to correspond to a received electronic plan can be selected for generating a workflow dataset representative of a standard workflow. The workflow dataset, including the selected set of role card objects, can be displayed via a graphical user interface. The GUI can facilitate scheduling, assignment, and execution of various tasks defined within the role card objects. Timed durations of executing such tasks can be compared to standard durations defined in each role card object of the workflow dataset, such that deviations from the standard durations can be determined. As variances can be problematic to operational efficiencies, techniques for dynamically generating, assigning, and analyzing datasets associated with identified problematic areas, such as variances, are provided.

Publication date: –
Applicant: Pfizer Inc.
Inventors: David Mcgettigan Scott

How are Pfizer Inc.’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/544,303 Cyclin Dependent Kinase Inhibitors Docketed New Case – Ready for Examination OPAP Central, Docket
17/539,948 Novel 3-Amino-Pyrrolo[3,4-C]Pyrazole-5(1H, 4H,6H) Carbaldehyde Derivatives Docketed New Case – Ready for Examination OPAP Central, Docket
17/607,341 Real-Time Tracking And Management Of Standard Workflows Docketed New Case – Ready for Examination OPAP Central, Docket